查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2019816

神經系統藥物市場：市場規模、佔有率、成長率、全球產業分析、按類型、應用和地區分類的分析以及未來預測（2026-2034 年）。

Neurology Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

神經系統藥物市場成長要素

由於神經系統疾病負擔日益加重以及藥物研發的進步，全球神經系統藥物市場正經歷顯著成長。預計到2025年，該市場規模將達到1,605.1億美元，2026年將成長至1,737億美元，到2034年將達到2,671.5億美元，預測期內（2026-2034年）的複合年成長率為9.10%。

到 2025 年，北美主導市場，這得益於其強大的醫療保健基礎設施、較高的疾病盛行率以及積極的研發活動。

神經系統藥物用於治療多種神經系統疾病，包括阿茲海默症、帕金森氏症、癲癇和多發性硬化症。公眾意識的提高、診斷率的提升以及治療選擇的增多，都促進了市場成長。

市場動態

市場促進因素

神經系統疾病盛行率的不斷上升是市場成長的主要驅動力。全球健康評估表明，神經系統疾病影響相當一部分人口，因此對有效治療方法的需求十分旺盛。

人口老化也是一個重要因素，因為老年人更容易罹患神經退化性疾病。此外，對包括生技藥品和基因療法在內的創新治療方法的研發投入不斷增加，也正在加速市場成長。

市場限制因素

儘管預計成長強勁，但治療神經系統疾病的高成本仍然是一項重大挑戰。藥物研發需要大規模臨床試驗和監管部門的核准，這導致治療成本高昂，患者可近性有限。

高昂的自付醫療費用和經濟負擔，尤其是在發展中地區，進一步阻礙了市場成長。

市場趨勢

技術進步正在改變神經系統藥物市場。人工智慧、腦機介面和先進的神經影像技術等創新正在改善診斷和治療效果。

另一個重要趨勢是生物製藥和單株療法的興起，它們能夠實現標靶治療，且副作用更少。這些治療方法正擴大應用於複雜神經系統疾病的治療。

此外，個人化醫療的日益普及正在重塑治療方法，使得根據每位患者的具體情況提供客製化治療成為可能。

市場機會與挑戰

個人化醫療的日益普及為市場相關人員帶來了巨大的機會。針對每位患者量身定做的治療方案能夠改善患者的治療效果和依從性，進而提高醫療保健的整體效率。

然而，神經系統疾病的複雜性帶來了巨大的挑戰。由於患者反應各異，且對疾病機制的了解有限，這些疾病的診斷和治療十分困難。此外，藥物如何有效傳遞到大腦仍然是一個科學難題，影響著治療效果。

細分分析

適應症

市場細分包括阿茲海默症、多發性硬化症、癲癇、帕金森氏症及其他疾病。由於患病率不斷上升和公眾意識提升活動的擴大，預計阿茲海默症細分市場將推動市場成長。

藥物類別

依藥物類別分類，市場可分為膽鹼酯酶抑制劑、NMDA受體拮抗劑、抗癲癇藥物和免疫調節劑。由於膽鹼酯酶抑制劑使用頻率高且近期有新產品核准，預計該細分市場將佔據主導地位。

透過行政途徑

市場分為口服和注射給藥途徑。口服給藥途徑因其給藥方便、患者遵守用藥性高而佔據市場主導地位，但注射給藥途徑的藥物也預計將穩定成長。

透過分銷管道

由於醫院藥房擁有龐大的患者群體和處方箋藥供應，因此佔據最大的市場佔有率。零售藥局和網路藥局也呈現穩定成長的態勢。

區域趨勢

北美洲

北美仍然是關鍵地區，預計到 2025 年市場規模將達到 916.8 億美元，到 2026 年將達到 993.9 億美元。強大的研究基礎設施和創新治療方法的廣泛應用正在推動這一成長。

歐洲

預計到 2025 年，歐洲的消費額將達到 447 億美元，在擴大宣傳活動和先進的醫療保健系統的支持下，預計到 2026 年將達到 483 億美元。

亞太地區

亞太地區在 2025 年達到 297.8 億美元，預計到 2026 年將成長至 327.3 億美元，主要得益於醫療保健服務的改善和病患數量的增加。

拉丁美洲、中東和非洲

在這些地區，由於醫療基礎設施的改善、疾病意識的提高以及政府的舉措，市場正在逐步擴大。

主要行業趨勢

  • 2025 年 5 月：賽諾菲收購 Vigil Neuroscience，以擴大其在神經病學領域的研發管線。
  • 2024 年 10 月：一種治療亞歷山大病的新治療方法被授予簡審類。
  • 2024 年 9 月：一種治療尼曼-匹克病 C 型的新療法獲得核准。
  • 2024年2月：一種用於治療進行進行性多發性硬化症的藥物在印度上市。

目錄

第1章：引言

第2章執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章 主要考慮因素

  • 主要神經系統疾病盛行率：依主要國家分類
  • 法律規範：依主要國家分類
  • 兌換狀態：依主要國家分類
  • 新產品發布和核准情況：按主要企業分類
  • 主要趨勢：企業合併、商業合作等。

第5章：全球神經系統藥物市場分析：洞察與預測（2021-2034）

  • 市場分析、考量與預測：依指標
    • 阿茲海默症
    • 多發性硬化症
    • 癲癇
    • 帕金森氏症
    • 其他
  • 市場分析、洞察與預測：按藥物類別分類
    • 膽鹼酯酶抑制劑
    • NMDA受體拮抗劑
    • 抗癲癇藥物
    • 免疫調節藥物
    • 其他
  • 市場分析、洞察與預測：按給藥途徑分類
    • 口服
    • 腸外
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 零售藥局和藥房
    • 網路藥房
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美神經系統藥物市場分析：探討與預測（2021-2034 年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲神經系統藥物市場分析：探討與預測（2021-2034 年）

  • 國家
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區神經系統藥物市場分析：洞察與預測（2021-2034）

  • 國家
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲神經系統藥物市場分析：探討與預測（2021-2034 年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東與非洲神經系統藥物市場分析：洞察與預測（2021-2034）

  • 國家
    • 南非
    • 波灣合作理事會（GCC）國家
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Eisai Co., Ltd.
    • Strategies
    • Biogen Inc.
    • Bayer AG
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Novartis AG
    • Merck KGaA
    • Sanofi
    • AbbVie Inc.
Product Code: FBI113562

Growth Factors of neurology drugs Market

The global neurology drugs market is experiencing significant growth due to the rising burden of neurological disorders and increasing advancements in pharmaceutical research. The market was valued at USD 160.51 billion in 2025 and is projected to grow to USD 173.70 billion in 2026, reaching USD 267.15 billion by 2034, exhibiting a CAGR of 9.10% during the forecast period (2026-2034).

North America dominated the market in 2025, supported by strong healthcare infrastructure, high disease prevalence, and robust research and development activities.

Neurology drugs are used to treat a wide range of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. Increasing awareness, improved diagnosis rates, and expanding treatment options are contributing to market expansion.

Market Dynamics

Market Drivers

The increasing prevalence of neurological disorders is a major factor driving market growth. According to global health estimates, neurological conditions affect a significant portion of the population, creating strong demand for effective treatment options.

The growing aging population is another key contributor, as elderly individuals are more prone to neurodegenerative diseases. Additionally, rising investments in research and development for innovative therapies, including biologics and gene-based treatments, are accelerating market growth.

Market Restraints

Despite strong growth prospects, the high cost of neurological treatments remains a major challenge. Drug development involves extensive clinical trials and regulatory approvals, making therapies expensive and limiting accessibility for patients.

High out-of-pocket healthcare expenses and affordability issues, especially in developing regions, further restrain market growth.

Market Trends

Technological advancements are transforming the neurology drugs market. Innovations such as artificial intelligence, brain-computer interfaces, and advanced neuroimaging techniques are improving diagnosis and treatment outcomes.

Another key trend is the rise of biologics and monoclonal therapies, which offer targeted treatment with fewer side effects. These therapies are increasingly used in managing complex neurological disorders.

Additionally, the growing adoption of personalized medicine is reshaping treatment approaches, enabling customized therapies based on individual patient profiles.

Market Opportunities and Challenges

The increasing focus on personalized medicine presents significant opportunities for market players. Tailored treatments improve patient outcomes and treatment adherence, enhancing overall healthcare efficiency.

However, the complexity of neurological disorders poses a major challenge. These conditions are difficult to diagnose and treat due to varying patient responses and limited understanding of disease mechanisms. Drug delivery to the brain also remains a scientific hurdle, impacting treatment effectiveness.

Segmentation Analysis

By Indication

The market is segmented into Alzheimer's disease, multiple sclerosis, epilepsy, Parkinson's disease, and others. The Alzheimer's disease segment is expected to dominate due to increasing prevalence and rising awareness initiatives.

By Drug Class

Based on drug class, the market includes cholinesterase inhibitors, NMDA receptor antagonists, antiepileptic drugs, and immunomodulatory drugs. The cholinesterase inhibitors segment is anticipated to lead due to high usage and recent product approvals.

By Route of Administration

The market is divided into oral and parenteral routes. The oral segment dominates due to ease of administration and high patient compliance, while parenteral drugs are expected to grow steadily.

By Distribution Channel

Hospital pharmacies hold the largest market share due to high patient inflow and prescription-based drug distribution. Retail and online pharmacies are also witnessing steady growth.

Regional Insights

North America

North America remains the leading region, with a market size of USD 91.68 billion in 2025, projected to reach USD 99.39 billion in 2026. Strong research infrastructure and high adoption of innovative therapies drive growth.

Europe

Europe accounted for USD 44.70 billion in 2025 and is expected to reach USD 48.30 billion in 2026, supported by increasing awareness programs and advanced healthcare systems.

Asia Pacific

Asia Pacific reached USD 29.78 billion in 2025 and is projected to grow to USD 32.73 billion in 2026, driven by improving healthcare access and rising patient populations.

Latin America & Middle East & Africa

These regions are gradually expanding due to improving healthcare infrastructure, increasing disease awareness, and government initiatives.

Competitive Landscape

The neurology drugs market is highly competitive, with major players focusing on innovation and expanding their product portfolios. Key companies include:

  • Novartis AG
  • Bayer AG
  • Pfizer Inc.
  • Sanofi
  • Biogen Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA

These companies are investing heavily in research and strategic collaborations to strengthen their market position.

Key Industry Developments

  • May 2025: Sanofi acquired Vigil Neuroscience to expand its neurology pipeline.
  • October 2024: Fast Track designation granted for a new therapy targeting Alexander disease.
  • September 2024: Approval of a novel drug for Niemann-Pick disease type C.
  • February 2024: Launch of advanced multiple sclerosis therapy in India.

Conclusion

The global neurology drugs market is poised for strong growth, driven by increasing prevalence of neurological disorders, advancements in drug development, and rising demand for personalized medicine. While high treatment costs and disease complexity present challenges, ongoing innovation and expanding healthcare access are expected to drive long-term market expansion. As pharmaceutical companies continue to invest in cutting-edge therapies, the market will play a crucial role in improving patient outcomes and addressing the global burden of neurological diseases.

Segmentation By Indication

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Epilepsy
  • Parkinson's Disease
  • Others

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonist
  • Antiepileptic Drugs
  • Immunomodulatory Drugs
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

  • North America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.S.
    • Canada
  • Europe (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Indication, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Neurological Disorders, By Key Countries/Regions
  • 4.2. Regulatory Framework, By Key Countries/Regions
  • 4.3. Reimbursement Scenario, By Key Countries/Regions
  • 4.4. New Product Launches & Approvals, By Key Players
  • 4.5. Key Industry Developments (Merger, Acquisition, Collaboration, etc.)

5. Global Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Indication
    • 5.1.1. Alzheimer's Disease
    • 5.1.2. Moltiple Sclerosis
    • 5.1.3. Epilepsy
    • 5.1.4. Parkinson's Disease
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Cholinesterase Inhibitors
    • 5.2.2. NMDA Receptor Antagonist
    • 5.2.3. Antiepileptic Drugs
    • 5.2.4. Immunomodolatory Drugs
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Indication
    • 6.1.1. Alzheimer's Disease
    • 6.1.2. Moltiple Sclerosis
    • 6.1.3. Epilepsy
    • 6.1.4. Parkinson's Disease
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Cholinesterase Inhibitors
    • 6.2.2. NMDA Receptor Antagonist
    • 6.2.3. Antiepileptic Drugs
    • 6.2.4. Immunomodolatory Drugs
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Indication
    • 7.1.1. Alzheimer's Disease
    • 7.1.2. Moltiple Sclerosis
    • 7.1.3. Epilepsy
    • 7.1.4. Parkinson's Disease
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Cholinesterase Inhibitors
    • 7.2.2. NMDA Receptor Antagonist
    • 7.2.3. Antiepileptic Drugs
    • 7.2.4. Immunomodolatory Drugs
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Indication
    • 8.1.1. Alzheimer's Disease
    • 8.1.2. Moltiple Sclerosis
    • 8.1.3. Epilepsy
    • 8.1.4. Parkinson's Disease
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Cholinesterase Inhibitors
    • 8.2.2. NMDA Receptor Antagonist
    • 8.2.3. Antiepileptic Drugs
    • 8.2.4. Immunomodolatory Drugs
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.5.1. China
    • 8.5.2. India
    • 8.5.3. Japan
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Indication
    • 9.1.1. Alzheimer's Disease
    • 9.1.2. Moltiple Sclerosis
    • 9.1.3. Epilepsy
    • 9.1.4. Parkinson's Disease
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Cholinesterase Inhibitors
    • 9.2.2. NMDA Receptor Antagonist
    • 9.2.3. Antiepileptic Drugs
    • 9.2.4. Immunomodolatory Drugs
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Neurology Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Indication
    • 10.1.1. Alzheimer's Disease
    • 10.1.2. Moltiple Sclerosis
    • 10.1.3. Epilepsy
    • 10.1.4. Parkinson's Disease
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Cholinesterase Inhibitors
    • 10.2.2. NMDA Receptor Antagonist
    • 10.2.3. Antiepileptic Drugs
    • 10.2.4. Immunomodolatory Drugs
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 10.5.1. South Africa
    • 10.5.2. GCC
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Eisai Co., Ltd.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT, etc.
    • 11.2.2. Strategies
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT, etc.
    • 11.2.3. Biogen Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT, etc.
    • 11.2.4. Bayer AG
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT, etc.
    • 11.2.5. Pfizer Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT, etc.
    • 11.2.6. Johnson & Johnson Services, Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. Financials (Based on Availability)
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. SWOT, etc.
    • 11.2.7. Novartis AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. Financials (Based on Availability)
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. SWOT, etc.
    • 11.2.8. Merck KGaA
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. Financials (Based on Availability)
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. SWOT, etc.
    • 11.2.9. Sanofi
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. Financials (Based on Availability)
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. SWOT, etc.
    • 11.2.10. AbbVie Inc.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. Financials (Based on Availability)
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. SWOT, etc.

List of Tables

  • Table 1: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 2: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 3: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 4: Global Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 5: Global Neurology Drugs Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 7: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 8: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 9: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 10: North America Neurology Drugs Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 12: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 13: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 14: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 15: Europe Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 16: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 17: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 18: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 19: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 21: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 22: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 23: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 24: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 25: Latin America Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034
  • Table 26: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Indication, 2021-2034
  • Table 27: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Drug Class, 2021-2034
  • Table 28: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Neurology Drugs Market Revenue (USD billion) Forecast, By Country/Sub-Region, 2021-2034

List of Figures

  • Figure 1: Global Neurology Drugs Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Neurology Drugs Market Value Share (%), By Indication, 2025 & 2034
  • Figure 3: Global Neurology Drugs Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 4: Global Neurology Drugs Market Value Share (%), By Route of Administration, 2025 & 2034
  • Figure 5: Global Neurology Drugs Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 6: Global Neurology Drugs Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Neurology Drugs Market Value (USD billion), By Indication, 2025 & 2034
  • Figure 8: North America Neurology Drugs Market Value Share (%), By Indication, 2025
  • Figure 9: North America Neurology Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 10: North America Neurology Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 11: North America Neurology Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 12: North America Neurology Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 13: North America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 14: North America Neurology Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 15: North America Neurology Drugs Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Neurology Drugs Market Value Share (%), By Country, 2025
  • Figure 17: Europe Neurology Drugs Market Value (USD billion), By Indication, 2025 & 2034
  • Figure 18: Europe Neurology Drugs Market Value Share (%), By Indication, 2025
  • Figure 19: Europe Neurology Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 20: Europe Neurology Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 21: Europe Neurology Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 22: Europe Neurology Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 23: Europe Neurology Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 24: Europe Neurology Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 25: Europe Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 26: Europe Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 27: Asia Pacific Neurology Drugs Market Value (USD billion), By Indication, 2025 & 2034
  • Figure 28: Asia Pacific Neurology Drugs Market Value Share (%), By Indication, 2025
  • Figure 29: Asia Pacific Neurology Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 30: Asia Pacific Neurology Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 31: Asia Pacific Neurology Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Neurology Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 33: Asia Pacific Neurology Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Neurology Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 35: Asia Pacific Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 36: Asia Pacific Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 37: Latin America Neurology Drugs Market Value (USD billion), By Indication, 2025 & 2034
  • Figure 38: Latin America Neurology Drugs Market Value Share (%), By Indication, 2025
  • Figure 39: Latin America Neurology Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 40: Latin America Neurology Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 41: Latin America Neurology Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 42: Latin America Neurology Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 43: Latin America Neurology Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Neurology Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 45: Latin America Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 46: Latin America Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 47: Middle East & Africa Neurology Drugs Market Value (USD billion), By Indication, 2025 & 2034
  • Figure 48: Middle East & Africa Neurology Drugs Market Value Share (%), By Indication, 2025
  • Figure 49: Middle East & Africa Neurology Drugs Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 50: Middle East & Africa Neurology Drugs Market Value Share (%), By Drug Class, 2025
  • Figure 51: Middle East & Africa Neurology Drugs Market Value (USD billion), By Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Neurology Drugs Market Value Share (%), By Route of Administration, 2025
  • Figure 53: Middle East & Africa Neurology Drugs Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Neurology Drugs Market Value Share (%), By Distribution Channel, 2025
  • Figure 55: Middle East & Africa Neurology Drugs Market Value (USD billion), By Country/Sub-Region, 2025 & 2034
  • Figure 56: Middle East & Africa Neurology Drugs Market Value Share (%), By Country/Sub-Region, 2025
  • Figure 57: Global Neurology Drugs Market Share (%), By Company, 2025